JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Evercore ISI initiated coverage on Sykes Enterprises (NASDAQ:SYKE) with an Outperform rating and a $10.00 price target.
The research firm highlighted nimacimab, describing it as "the only weekly SC large molecule CB1 inhibitor in development" that can address critical gaps in obesity care.
Evercore ISI identified three potential applications for nimacimab: as a GLP-1 off-ramp/maintenance option, as combination therapy in severe obesity, and as a non-incretin monotherapy option for select patients.
The firm noted that peripheral CB1 blockade improves metabolic signaling without the central nervous system liabilities that affected first-generation CB1 agents, though the 26-week phase 2a readout expected in late third quarter or early fourth quarter of 2025 will be the next major test.
Evercore ISI believes nimacimab can clear its target of 5% placebo-adjusted weight loss in this trial based on its potency and peripheral pharmacokinetic profile, and noted its differentiation from competitors through its subcutaneous weekly formulation, lower CNS penetration, and its function as a negative allosteric inverse agonist.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.